Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lymphoproliferative disease in organ transplant recipients.

Literature DB >> 1664986

Lymphoproliferative disease in organ transplant recipients.

M A Nalesnik¹.

Abstract

Entities: Disease

Mesh：

Year: 1991 PMID： 1664986 DOI： 10.1007/bf00201469

Source DB: PubMed Journal: Springer Semin Immunopathol ISSN： 0344-4325

× No keyword cloud information.

61 in total

1. Epstein-Barr viral genome in lymph nodes from patients with Hodgkin's disease may not be specific to Reed-Sternberg cells.

Authors: A Masih; D Weisenburger; M Duggan; J Armitage; R Bashir; D Mitchell; R Wickert; D T Purtilo
Journal: Am J Pathol Date: 1991-07 Impact factor: 4.307

Review 2. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

Authors: D W Hanto; G Frizzera; K J Gajl-Peczalska; R L Simmons
Journal: Transplantation Date: 1985-05 Impact factor: 4.939

3. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

Authors: J J Siekierka; S H Hung; M Poe; C S Lin; N H Sigal
Journal: Nature Date: 1989-10-26 Impact factor: 49.962

4. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors: F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal: J Virol Date: 1990-05 Impact factor: 5.103

Review 5. The mechanisms of action of cyclosporine.

Authors: B M Foxwell; B Ruffel
Journal: Cardiol Clin Date: 1990-02 Impact factor: 2.213

6. Immunohistologic identification of Epstein-Barr virus-induced hepatitis reactivation after OKT-3 therapy following orthotopic liver transplant.

Authors: R S Markin; R P Wood; B W Shaw; B Brichacek; D T Purtilo
Journal: Am J Gastroenterol Date: 1990-08 Impact factor: 10.864

7. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Authors: K W Moore; P Vieira; D F Fiorentino; M L Trounstine; T A Khan; T R Mosmann
Journal: Science Date: 1990-06-08 Impact factor: 47.728

8. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

Authors: A Fischer; S Blanche; J Le Bidois; P Bordigoni; J L Garnier; P Niaudet; F Morinet; F Le Deist; A M Fischer; C Griscelli
Journal: N Engl J Med Date: 1991-05-23 Impact factor: 91.245

9. Molecular genetic analysis of lymphoid tumors arising after organ transplantation.

Authors: J Locker; M Nalesnik
Journal: Am J Pathol Date: 1989-12 Impact factor: 4.307

10. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

Authors: M Ho; G Miller; R W Atchison; M K Breinig; J S Dummer; W Andiman; T E Starzl; R Eastman; B P Griffith; R L Hardesty
Journal: J Infect Dis Date: 1985-11 Impact factor: 5.226

7 in total

7. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders.

Authors: H J Delecluse; E Kremmer; J P Rouault; C Cour; G Bornkamm; F Berger
Journal: Am J Pathol Date: 1995-05 Impact factor: 4.307

7 in total

Lymphoproliferative disease in organ transplant recipients.

1. Epstein-Barr viral genome in lymph nodes from patients with Hodgkin's disease may not be specific to Reed-Sternberg cells.

Review 2. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

3. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin.

4. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Review 5. The mechanisms of action of cyclosporine.

6. Immunohistologic identification of Epstein-Barr virus-induced hepatitis reactivation after OKT-3 therapy following orthotopic liver transplant.

7. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

8. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

9. Molecular genetic analysis of lymphoid tumors arising after organ transplantation.

10. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

1. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

2. A 26-year-old man with Hodgkin's disease and rapidly progressive pancytopenia.

Review 3. Interferon-alpha and its effects on post-transplant lymphoproliferative disorders.

4. Lymphoproliferative disease in mice infected with murine gammaherpesvirus 68.

5. Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice.

6. LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha.

7. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders.